Table 3.

Skin cancer tumor board impact (N=37).

Impact of meeting on patient care
No impact	0/37 (0%)
Minimal impact	1/37 (3%)
Moderate impact	12/37 (32%)
Significant impact	24/37 (65%)
Value of meeting
Enhanced communication among physicians	37/37 (100%)
Continuing medication education for physicians	27/37 (73%)
Encouraged use of most recent guidelines for management	29/37 (78%)
More treatment options for patients	34/37 (92%)
Reduced number of visits for patients	15/37 (41%)
Opportunity for physicians, nurses, allied health professionals to discuss cases together	37/37 (100%)
Drives development of new research protocols	24/37 (65%)
Increased enrollment of patients in clinical trials	25/37 (68%)
Improved standardization of care*	2/37 (5%)
Barriers to setting up meeting
Finding a common date and time	23/37 (62%)
Lack of administrative support	7/37 (19%)
Lack of specialties	9/37 (24%)
Finding a physician to take on leadership role	3/37 (8%)
Lack of time to prepare for meeting	9/37 (24%)
High caseload	8/37 (22%)
Lack of financial support	13/37 (35%)
None of the above	6/37 (16%)
Lack of technological support*	1/37 (3%)
Time constraints of meeting*	1/37 (3%)
Competing tumor boards*	1/37 (3%)

^*Answer was written in by one or more respondents under the “other” option, and was not listed as one of the multiple choice options.